Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
about
A strategy to model nonmonotonic dose-response curve and estimate IC50Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionDistinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.HIV-1 diversity after a class switch failure.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell cultureShort communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake VictoriaHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTClinical significance of human immunodeficiency virus type 1 replication fitness.HIV-1 mutational pathways under multidrug therapy.Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review.Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyFactors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
P2860
Q28535044-361CE373-2E1B-43E1-A869-036F25C10EC9Q33649563-59AF08A4-C9E7-4E86-86E9-059AD582DF91Q33785915-F46A0D5B-9B6C-4CA3-8D98-CEEFCBB02E02Q33872810-D354A7F2-8BF8-41C5-B693-5EF78E9236B7Q33973857-54841435-180E-471C-9BFA-08BF63BCC2BCQ34289973-3504B3EE-35FF-4FD9-9A33-FB98B5CF3F30Q34399268-761FA214-53B3-4635-AD87-977238B3DFA7Q34489422-C3C35514-3607-4ADF-91FC-425C3B209B48Q34615228-3250A6A6-006A-4273-805F-3406A4335A4CQ34737547-F2FC93A1-3773-46ED-BE09-4B16826A9F24Q35142729-2B5B5D77-A460-4AAA-8462-D90776D0B9EEQ35363594-83D3CFF8-268B-4845-BD1E-379E0CD5435BQ36099251-7E90C104-EA80-4C87-ADDF-B43D144E6136Q36250342-C32D2BED-560E-44AC-9031-AB579C242D03Q36397557-5C9CB262-0539-46E9-846A-9573416660CEQ36718337-53FAD1B2-B402-449A-8C0E-2E318091FDA5Q36795920-CDF715D1-6FDA-4D0B-9C35-36D59DD8AE0FQ36900010-2B8752ED-2F34-4E93-959C-895FD8427455Q36969857-19AD7AAF-B27C-4CAA-889A-00840CA568F7Q38264403-DC207181-621B-4272-8D7A-DA7D29313DB8Q38543385-1F627E45-5AD7-4B35-9E3C-7F96C0828713Q39174700-D1926BED-79C1-41E3-8883-26D602E2FC2BQ41668874-E544B327-ED8A-4C20-BA81-06B57E6F53D1Q41922832-175AFE92-B2A5-4E55-AD4A-AAF1DB3186C7Q42159090-5F27E5D7-8BD4-4962-A937-6F8F185A27F1Q42430831-3474ADDA-9B66-48D0-9F31-78C31799808DQ44741225-6C410D3C-BD25-46E9-879B-F17AEBA2FBBE
P2860
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Relative replication fitness o ...... side resistance mutation L74V.
@ast
Relative replication fitness o ...... side resistance mutation L74V.
@en
type
label
Relative replication fitness o ...... side resistance mutation L74V.
@ast
Relative replication fitness o ...... side resistance mutation L74V.
@en
prefLabel
Relative replication fitness o ...... side resistance mutation L74V.
@ast
Relative replication fitness o ...... side resistance mutation L74V.
@en
P2093
P2860
P1433
P1476
Relative replication fitness o ...... side resistance mutation L74V.
@en
P2093
Carrie Dykes
Christine E Koval
Jiong Wang
Lisa M Demeter
P2860
P304
P356
10.1016/J.VIROL.2006.05.021
P407
P577
2006-06-21T00:00:00Z